Thursday, February 23, 2023
Eko has announced the launch of the SENSORA™ Cardiac Disease Monitoring Platform.
The current version of SENSORA™ includes both AI and Care Pathway Analytics software, which objectively identifies structural murmurs, a sign of valvular heart disease, and provides downstream visibility and metrics of the patient journey through the healthcare system.
The stethoscope, one of the most widely used medical instruments in the world, is combined with the most recent developments in applied machine learning to create the cardiovascular disease detection tool known as SENSORA™.
Eko has invented a detection tool that will grow as the company develops apps for more cardiac conditions by using its digital stethoscopes to record and analyze electrical signals and heart sounds.
During a routine visit with their primary care physician, patients with valvular heart disease (VHD) can be more reliably and accurately diagnosed with valvular heart disease (VHD) with the SENSORA™ FDA-cleared structural murmur detection.
A low ejection fraction detection algorithm (named "ELEFT") to detect a weak heart pump, which is present in half of heart failure patients, and an algorithm to detect and stratify pulmonary hypertension are two novel machine learning algorithms that the company is developing in addition to its current portfolio of five FDA 510(k) cleared digital solutions from Eko.
By developing cutting-edge solutions that address their requirements, enable the early detection of heart and lung diseases, and save lives, Eko is dedicated to having an effect on patients and clinicians.
